Dr. West Brings over 25 Years of Trusted
Clinical Expertise in Thoracic Oncology
Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the
“Company”) today announced that Howard “Jack” West, MD, has joined
Summit Therapeutics as Vice President of Clinical Development
focused on lung cancer.
“Dr. West brings a wealth of experience, and his knowledge in
treating lung cancer patients is unrivaled,” stated Dr. Maky
Zanganeh, Chief Executive Officer and President of the Company. “To
bring a key lung cancer expert the stature of Dr. West speaks
volumes about Team Summit and our mission to make a significant,
positive difference in the lives of patients facing this terrible
disease. We are thrilled to welcome Jack to our team.”
Dr. West joins Summit from City of Hope, one of the nation’s
leading cancer treatment and research centers. At City of Hope, he
was the Vice President of Network Strategy at AccessHope, an
enterprise that provides remote expertise from cancer
sub-specialists for patients around the US, as well as an Associate
Professor and practicing medical oncologist. Dr. West brings over
25 years of experience as a practicing thoracic oncologist. Prior
to joining City of Hope, Dr. West spent over 15 years at Providence
Health & Services, including time as the Medical Director of
the Thoracic Oncology Program. As a practicing physician, Dr. West
has been a principal investigator in over 20 clinical trials in
lung cancer. Dr. West is also the Founder and former President of
GRACE, the Global Resource for Advancing Cancer Education, and the
President of Go West Health Care Consulting, providing in depth
knowledge about current and emerging cancer treatments. He has been
responsible for publishing treatment guidelines and medical
provider point-of-care resource guides such as Medscape and
UpToDate. Dr. West earned his medical degree from Harvard Medical
School, was the Howard Hughes Medical Student Research Fellow at
Massachusetts General Hospital, and did his medical oncology
fellowship training at the University of Washington Fred Hutchinson
Cancer Research Center.
“Bolstering our team with someone with the breadth and depth of
experience and expertise such as Jack West is an honor for me and
Team Summit,” added Dr. Allen S. Yang, Chief Medical Officer at
Summit. “Dr. West is a respected thoracic oncology expert who has
worked with nearly every treatment in lung cancer over the past 25
years – whether through providing patient care, leading clinical
trials, or disseminating treatment guidance. His stature and
expertise are valued resources as we continue to advance and
develop our novel, potentially first-in-class bispecific antibody,
ivonescimab*.”
“Throughout my career, in addition to caring for patients, I
have focused on providing knowledge and access to the best possible
care in the particularly challenging field of thoracic oncology,”
noted Dr. West. “While treatment options have advanced greatly over
the past 25 years, every lung cancer clinic illustrates the ongoing
need for additional advances. The opportunity to work with an
outstanding team at Summit, contributing to the development of
ivonescimab, an investigational product with great potential,
offers me a new path to improving the lives of patients.”
Summit Therapeutics’ Mission Statement
To build a viable, long-lasting health care organization that
assumes full responsibility for designing, developing, trial
execution and enrollment, regulatory submission and approval, and
successful commercialization of patient, physician, caregiver, and
societal-friendly medicinal therapy intended to: improve quality of
life, increase potential duration of life, and resolve serious
medical healthcare needs. To identify and control promising product
candidates based on exceptional scientific development and
administrational expertise, develop our products in a rapid,
cost-efficient manner, and to engage commercialization and/or
development partners when appropriate.
We accomplish this by building a team of world class
professional scientists and business administrators that apply
their experience and knowledge to this mission. Team Summit exists
to pose, strategize, and execute a path forward in medicinal
therapeutic health care that places Summit in a well-deserved, top
market share, leadership position. Team Summit assumes full
responsibility for stimulating continuous expansion of knowledge,
ability, capability, and well-being for all involved stakeholders
and highly-valued shareholders.
About Ivonescimab
Ivonescimab, known as SMT112 in the United States, Canada,
Europe, and Japan (Summit’s license territories), and as AK112 in
China and Australia, is a novel, potential first-in-class
investigational bispecific antibody combining the effects of
immunotherapy via a blockade of PD-1 with the anti-angiogenesis
effects associated with blocking VEGF into a single molecule.
Ivonescimab was discovered by Akeso Inc. (HKEX Code: 9926.HK) and
is currently engaged in multiple Phase III clinical trials. Summit
has begun its clinical development of ivonescimab in NSCLC,
enrolling the first patient in its license territory in 2023, with
multiple Phase III clinical trials intended to be initiated in
2023. Over 825 patients have been treated with ivonescimab in
clinical studies in China and Australia, with enrollment beginning
recently in the United States.
About Summit Therapeutics
Summit was founded in 2003 and our shares are listed on the
Nasdaq Global Market (symbol ‘SMMT’). We are headquartered in Menlo
Park, California, and we have additional offices in Oxford, UK.
For more information, please visit https://www.smmttx.com and
follow us on X (formerly Twitter) @summitplc.
Summit Forward-looking Statements
Any statements in this press release about the Company’s future
expectations, plans and prospects, including but not limited to,
statements about the clinical and preclinical development of the
Company’s product candidates, entry into and actions related to the
Company’s partnership with Akeso Inc., the therapeutic potential of
the Company’s product candidates, the potential commercialization
of the Company’s product candidates, the timing of initiation,
completion and availability of data from clinical trials, the
potential submission of applications for marketing approvals, the
impact of the COVID-19 pandemic on the Company’s operations and
clinical trials, potential acquisitions and other statements
containing the words "anticipate," "believe," "continue," "could,"
"estimate," "expect," "intend," "may," "plan," "potential,"
"predict," "project," "should," "target," "would," and similar
expressions, constitute forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995.
Actual results may differ materially from those indicated by such
forward-looking statements as a result of various important
factors, including the results of our evaluation of the underlying
data in connection with the development and commercialization
activities for SMT112, the outcome of discussions with regulatory
authorities, including the Food and Drug Administration, the
uncertainties inherent in the initiation of future clinical trials,
availability and timing of data from ongoing and future clinical
trials, the results of such trials, and their success, and global
public health crises, including the coronavirus COVID-19 outbreak,
that may affect timing and status of our clinical trials and
operations, whether preliminary results from a clinical trial will
be predictive of the final results of that trial or whether results
of early clinical trials or preclinical studies will be indicative
of the results of later clinical trials, whether business
development opportunities to expand the Company’s pipeline of drug
candidates, including without limitation, through potential
acquisitions of, and/or collaborations with, other entities occur,
expectations for regulatory approvals, laws and regulations
affecting government contracts and funding awards, availability of
funding sufficient for the Company’s foreseeable and unforeseeable
operating expenses and capital expenditure requirements and other
factors discussed in the "Risk Factors" section of filings that the
Company makes with the Securities and Exchange Commission. Any
change to our ongoing trials could cause delays, affect our future
expenses, and add uncertainty to our commercialization efforts, as
well as to affect the likelihood of the successful completion of
clinical development of SMT112. Accordingly, readers should not
place undue reliance on forward-looking statements or information.
In addition, any forward-looking statements included in this press
release represent the Company’s views only as of the date of this
release and should not be relied upon as representing the Company’s
views as of any subsequent date. The Company specifically disclaims
any obligation to update any forward-looking statements included in
this press release.
* Ivonescimab is an investigational therapy that is not approved
by any regulatory agency.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231019060130/en/
Contact Summit Investor Relations: Dave Gancarz Chief
Business & Strategy Officer investors@smmttx.com
Summit Therapeutics (NASDAQ:SMMT)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Summit Therapeutics (NASDAQ:SMMT)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024